Search results
SunCoke Energy, Inc. (NYSE:SXC) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 hours agoSunCoke Energy, Inc. (NYSE:SXC) Q1 2024 Earnings Call Transcript May 1, 2024 SunCoke Energy, Inc....
We are making another buy of this retailer ahead of the coming rebound in PCs
CNBC· 2 days agoFollowing the trade, Jim Cramer's Charitable Trust will own 1,000 shares of BBY, increasing its...
Stanley Black & Decker's earnings beat fails to satisfy Wall Street. Here's why we bought the dip
CNBC· 2 hours agoStanley Black & Decker overcame a soft demand environment to deliver a top and bottom line beat...
Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
CNBC· 3 hours agoBausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses —...
Global Industrial Company (NYSE:GIC) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoGlobal Industrial Company (NYSE:GIC) Q1 2024 Earnings Call Transcript April 30, 2024 Global...
Here’s Why MGP Ingredients (MGPI) Declined in Q1
Insider Monkey via Yahoo Finance· 8 hours agoSouthernSun Asset Management, LLC, an investment management firm, released its “SouthernSun Small Cap Strategy” first quarter 2024 investor letter. A...
Linde's guidance leaves investors wanting more. We're saying thanks to the sellers
CNBC· 4 hours agoShares of Linde fell on Thursday after the industrial gas giant reported mixed first-quarter results...
Roku, Inc. (NASDAQ:ROKU) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoRoku, Inc. (NASDAQ:ROKU) Q1 2024 Earnings Call Transcript April 25, 2024 Roku, Inc. beats earnings...
Starbucks gets a price target cut after a brutal quarterly miss and light guidance
CNBC· 2 days agoStarbucks shares plummeted Tuesday evening by roughly 11.5% after the coffee giant delivered a much...
Eli Lilly assures investors it can overcome the high-quality problem of too much demand
CNBC· 2 days agoThe numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Eli Lilly ...